Literature DB >> 22228137

Expression of tumor suppressor gene ING4 in ovarian carcinoma is correlated with microvessel density.

Yinglan Liu1, Liqian Yu, Yingwei Wang, Yaling Zhang, Yingchao Wang, Guangmei Zhang.   

Abstract

PURPOSE: Angiogenesis, estimated by microvessel density (MVD), has been shown to predict poor progression-free survival in women with advanced epithelial ovarian cancer. Inhibitor of growth (ING) family proteins inhibit angiogenesis in a number of cancers. We evaluated the role of ING4 in regulation of angiogenesis in patients with epithelial ovarian cancer.
METHODS: Semi-quantitative RT-PCR was used to determine ING4 mRNA levels in 40 ovarian cancer patients and 40 normal controls. Also, we used immunohistochemistry to evaluate (1) ING4 protein expression levels and (2) the level of MVD by staining CD34, a microvessel marker, in these patients. Through statistical analysis, the possible correlation between the ING4 expression and angiogenesis was explored.
RESULTS: ING4 mRNA and protein were significantly downregulated in all ovarian cancer patients compared to normal controls (P < 0.001). Endometrioid carcinoma tissue had significantly lower ING4 levels compared to serous or mucinous ovarian cancer. ING4 expression correlated negatively with stage and histological grade of ovarian cancers. MVD correlated negatively with ING4 protein and mRNA levels (ρ = -0.865; P < 0.001 and ρ = -0.724; P < 0.001, respectively).
CONCLUSIONS: Loss of ING4 may promote microvessel formation and plays a role in facilitating the development of ovarian cancer. Although the specific mechanisms are not yet understood, our data suggest that ING4 may be a promising target for the treatment for ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228137     DOI: 10.1007/s00432-011-1099-5

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  42 in total

1.  Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.

Authors:  Jennifer M Rubatt; Kathleen M Darcy; Alan Hutson; Sarah M Bean; Laura J Havrilesky; Lisa A Grace; Andrew Berchuck; Angeles Alvarez Secord
Journal:  Gynecol Oncol       Date:  2009-01-09       Impact factor: 5.482

Review 2.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

Review 3.  Regulation of HIF by prolyl hydroxylases: recruitment of the candidate tumor suppressor protein ING4.

Authors:  Abdullah Ozer; Richard K Bruick
Journal:  Cell Cycle       Date:  2005-09-19       Impact factor: 4.534

4.  Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study.

Authors:  A N Gordon; N Finkler; R P Edwards; A A Garcia; M Crozier; D H Irwin; E Barrett
Journal:  Int J Gynecol Cancer       Date:  2005 Sep-Oct       Impact factor: 3.437

5.  Downregulation and translocation of nuclear ING4 is correlated with tumorigenesis and progression of head and neck squamous cell carcinoma.

Authors:  Xiao-han Li; Keiji Kikuchi; Yang Zheng; Akira Noguchi; Hiroyuki Takahashi; Takeshi Nishida; Shinji Masuda; Xiang-hong Yang; Yasuo Takano
Journal:  Oral Oncol       Date:  2011-03       Impact factor: 5.337

6.  Down-regulation of ING4 is associated with initiation and progression of lung cancer.

Authors:  Qiu-shi Wang; Ming Li; Lin-you Zhang; Yan Jin; Dan-dan Tong; Yang Yu; Jing Bai; Qi Huang; Fang-Li Liu; An Liu; Ki-Young Lee; Song-bin Fu
Journal:  Histopathology       Date:  2010-08       Impact factor: 5.087

7.  Adenovirus-mediated ING4 expression suppresses lung carcinoma cell growth via induction of cell cycle alteration and apoptosis and inhibition of tumor invasion and angiogenesis.

Authors:  Yufeng Xie; Haifeng Zhang; Weihua Sheng; Jim Xiang; Zhenmin Ye; Jicheng Yang
Journal:  Cancer Lett       Date:  2008-09-11       Impact factor: 8.679

8.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Authors:  Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

9.  Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.

Authors:  Russell J Schilder; Michael W Sill; Roger B Lee; Tanya J Shaw; Mary K Senterman; Andres J Klein-Szanto; Zoe Miner; Barbara C Vanderhyden
Journal:  J Clin Oncol       Date:  2008-07-10       Impact factor: 44.544

10.  Decreased expression of inhibitor of growth 4 correlated with poor prognosis of hepatocellular carcinoma.

Authors:  Feng Fang; Lai-Bang Luo; Yi-Ming Tao; Fan Wu; Lian-Yue Yang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02       Impact factor: 4.254

View more
  15 in total

1.  ING4 enhances paclitaxel's effect on colorectal cancer growth in vitro and in vivo.

Authors:  Liyu Cao; Shunhua Chen; Cong Zhang; Cong Chen; Nana Lu; Yan Jiang; Yongping Cai; Yu Yin; Jianming Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Identification of the inhibitor of growth protein 4 (ING4) as a potential target in prostate cancer therapy.

Authors:  Aymen Shatnawi; Sridhar A Malkaram; Tamer Fandy; Efrosini Tsouko
Journal:  Mol Cell Biochem       Date:  2019-11-27       Impact factor: 3.396

3.  Tumor suppressor ING4 overexpression contributes to proliferation and invasion inhibition in gastric carcinoma by suppressing the NF-κB signaling pathway.

Authors:  Shijie Li; Tianli Fan; Hongtao Liu; Jiangtao Chen; Changjiang Qin; Xuequn Ren
Journal:  Mol Biol Rep       Date:  2013-09-22       Impact factor: 2.316

4.  Expression of ING4 is negatively correlated with cellular proliferation and microvessel density in human glioma.

Authors:  Bin Shao; Enzhong Liu
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

Review 5.  INGs are potential drug targets for cancer.

Authors:  Runyun Zhang; Jianhua Jin; Juanjuan Shi; Yongzhong Hou
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-20       Impact factor: 4.553

Review 6.  Inhibitor of growth-4 is a potential target for cancer therapy.

Authors:  Shuping Yuan; Jianhua Jin; Juanjuan Shi; Yongzhong Hou
Journal:  Tumour Biol       Date:  2016-01-23

7.  Reduced expression and prognostic implication of inhibitor of growth 4 in human osteosarcoma.

Authors:  Dahang Zhao; Xiangjie Liu; Yunge Zhang; Zhaoming Ding; Feng Dong; Hongwei Xu; Baoxin Wang; Wenbo Wang
Journal:  Oncol Lett       Date:  2016-03-09       Impact factor: 2.967

8.  Overexpression of Inhibitor of Growth 4 Enhances Radiosensitivity in Non-Small Cell Lung Cancer Cell Line SPC-A1.

Authors:  Xuan Pan; Rui Wang; Haibo Bian; Wei De; Ping Zhang; Chenchen Wei; Zhaoxia Wang
Journal:  Technol Cancer Res Treat       Date:  2016-07-04

9.  MicroRNA-650 was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression.

Authors:  Jia-Yuan Huang; Shi-Yun Cui; Yi-Tian Chen; Hai-Zhu Song; Gui-Chun Huang; Bing Feng; Ming Sun; Wei De; Rui Wang; Long-Bang Chen
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

10.  ING4 regulates JWA in angiogenesis and their prognostic value in melanoma patients.

Authors:  J Lu; Y Tang; Y Cheng; G Zhang; A Yip; M Martinka; Z Dong; J Zhou; G Li
Journal:  Br J Cancer       Date:  2013-10-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.